Blueprint Medicines (STU:2L9) Ending Cash Position : €124.0 Mil (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines Ending Cash Position?

Blueprint Medicines's Ending Cash Position for the quarter that ended in Mar. 2025 was €124.0 Mil.

Blueprint Medicines's quarterly Ending Cash Position increased from Sep. 2024 (€90.9 Mil) to Dec. 2024 (€108.5 Mil) and increased from Dec. 2024 (€108.5 Mil) to Mar. 2025 (€124.0 Mil).

Blueprint Medicines's annual Ending Cash Position declined from Dec. 2022 (€117.9 Mil) to Dec. 2023 (€74.8 Mil) but then increased from Dec. 2023 (€74.8 Mil) to Dec. 2024 (€108.5 Mil).

Blueprint Medicines Ending Cash Position Historical Data

The historical data trend for Blueprint Medicines's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Ending Cash Position Chart

Blueprint Medicines Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

567.02

190.38

117.91

74.76

108.53

Blueprint Medicines Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Ending Cash Position	Get a 7-Day Free Trial															114.04	60.92	90.87	108.53	124.04

Blueprint Medicines Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Blueprint Medicines's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	77.855	+	30.67
	=	108.5

Blueprint Medicines's Ending Cash Position for the quarter that ended in Mar. 2025 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	105.116	+	18.919
	=	124.0

Blueprint Medicines Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BPMC:USA 0HOJ:UK 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines